BitGo Expands Regulated Crypto Trading Services in MENA 
OpenAI Eyes Massive 10GW Ohio Data Center Campus in Potential $500 Billion AI Infrastructure Deal 
Asics Considers Onitsuka Tiger Spinoff as Luxury Sneaker Brand Expands Globally 
China Trade Surplus Surges in May 2026 as Exports and AI-Driven Imports Accelerate 
Changchun Targets EV Growth as China’s Auto Industry Consolidation Accelerates 
OpenAI Files Confidential IPO Draft as AI Giants Race Toward Public Markets 
US Dollar Dips as Middle East Tensions Ease; Markets Await Key US Inflation Data 
Trump Signals Opposition to USMCA Renewal as U.S. Reviews Trade Relations with Canada and Mexico 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
ECB Set to Raise Interest Rates as Energy Shock Fuels Eurozone Inflation Concerns 
Oracle Stock Falls Despite Earnings Beat as Company Plans $40 Billion Financing for FY2027 
Asian Stocks Rebound as AI and Chip Shares Recover; Easing Iran Tensions Boost Sentiment 
Intesa Sanpaolo Launches €30.6 Billion Bid for Monte dei Paschi to Drive Italian Banking Consolidation 
Asian Stocks Slide as Tech Selloff Deepens and US-Iran Conflict Escalates 
Wall Street Ends Mixed as Iran Tensions, OpenAI IPO Filing, and Inflation Concerns Weigh on Markets 
China Inflation Misses Forecast as Consumer Spending Stays Weak, Producer Prices Surge 
Samsung Electronics’s executive chairman, Lee Jae Yong, has been holding meetings with leaders of the leading biopharmaceutical and biotechnology companies to forge joint ventures or enter into partnership deals.
The Samsung Electronics chief reportedly met up with global executives of some leading brands in the biotech and biopharma industry, including Johnson & Johnson’s chief executive officer, Joaquin Duato; Biogen’s chief, Christopher Viehbacher; Bristol Myers Squibb’s CEO, Giovanni Caforio; Kevin Ali, Organon’s CEO; and Noubar Afeyan of Flagship Pioneering.
Lee held meetings with them during his recent trip to the United States. Korea Joongang Daily reported that the Samsung leader has a goal of securing partnership agreements with them as he is seeing the biopharma and biotech fields as the company’s new growth drivers.
The Samsung chairman also commented during his trip, "The starting point is not important, but bold and persistent challenges set victory apart from defeat. Let us continue the success story of chips with bio."
In any case, Lee Jae Yong is trying to get contracts for the company’s CMDO arm, Samsung Biologics, which is currently the largest contract manufacturing and development organization in the world based on production capacity.
While it is a latecomer in this market, Samsung Biologics is doing fairly well since it was first established in 2011. Samsung Electronics owns 31.22% of shares in its affiliate CMDO firm.
"The bio-industry is a field with high barriers to entry, requiring not only production technology and R&D capabilities but also trust and reputation building for long-term collaboration,” The Korea Times quoted Samsung as saying in a statement regarding the chairman's move to seek collaborations with US bio companies. “Lee's wide global network is expected to serve as a lever for Samsung's bio business to expand collaboration with big pharmaceutical companies and create future growth opportunities."
